Method of treating lower urinary tract disorders

Abstract

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

Description

BACKGROUND OF THE INVENTION Lower urinary tract disorders affect the quality of life of millions of men and women in the United States every year. While the kidneys filter blood and produce urine, the lower urinary tract functions to store and periodically eliminate urine and includes all other parts of the urinary tract except the kidneys. Generally, the lower urinary tract includes the ureters, the urinary bladder, sphincter and the urethra. Disorders of the lower urinary tract include overactive bladder, interstitial cystitis, prostatitis, prostadynia and benign prostatic hyperplasia. Overactive bladder is a treatable medical condition that is estimated to affect 17 to 20 million people in the United States. Symptoms of overactive bladder can include urinary frequency, urinary urgency, urinary urge incontinence (accidental loss of urine) due to a sudden and unstoppable need to urinate, nocturia (the disturbance of nighttime sleep because of the need to urinate) or enuresis resu...

AI Technical Summary

Benefits of technology

"The patent describes a method for treating lower urinary tract disorders such as urinary frequency, urinary urgency, urinary urge incontinence, nocturia, and enuresis in subjects in need of treatment. The method involves administering a compound that has both 5-HT3 receptor antagonist and NARI activity. The invention also relates to pharmaceutical compositions containing the compound for treating lower urinary tract disorders. The technical effect of the invention is to provide an effective treatment for lower urinary tract disorders with a single compound that targets both receptors, reducing the likelihood of side effects and improving efficacy."

Problems solved by technology

Destruction of the sensory nerve fibers, either from a crushing injury to the sacral region of the spinal cord, or from a disease that causes damage to the dorsal root fibers as they enter the spinal cord can also lead to overactive bladder.

In addition, damage to the spinal cord or brain stem causing interruption of transmitted signals can lead to abnormalities in micturition.

Currently there are no clinically approved applications of central nervous system oriented pharmacotherapies for treating lower urinary tract disorders, such as overactive bladder.

However, treatment with antimuscarinics suffers from limited efficacy and side effects such as dry mouth, dry eyes, dry vagina, blurred vision, cardiac side effects, such as palpitations and arrhythmia, drowsiness, urinary retention, weight gain, hypertension and constipation, which have proven difficult for some individuals to tolerate.

Many interstitial cystitis patients also experience headaches as well as gastrointestinal and skin problems.

As such, lack of patient compliance often results in unsuccessful treatment.

In addition, treatment with ELMIRON® is not effective in a large percentage of patients.

However, in view of the unknown cause of interstitial cystitis and the suggestion that the disorder is multifactorial in origin, these additional therapies have not provided adequate relief of the associated symptoms.

Currently, there are no established treatments for prostatitis and prostadynia.

Antibiotics are often prescribed, but with little evidence of efficacy.

COX-2 selective inhibitors and α-adrenergic blockers and have been suggested as treatments, but their efficacy has not been established.

However, complications can arise through the use of some of these treatments, including retrograde ejaculation, impotence, postoperative urinary tract infection and some urinary incontinence.

However, these treatments have proven only minimally to moderately effective for some patients.

Images